Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
|Podcasts|January 28, 2021
The Cutaneous Connection- Episode 16: COVID-19 Vaccine and Dermal Fillers
Author(s)Morgan Petronelli
Recent reports have been surfacing in regard to adverse reactions in dermal fillers patients who have also received the COVID-19 vaccine. Whitney Bowe, MD, New York City, New York, discusses this phenomenon and provides some tips for preventing and treating these side effects.
Advertisement
Advertisement
Related to this article
Genetic study links higher BMI to looking older, but causality stays unclear; Mendelian randomization flags shared signals and candidate genes needing validation.
Merz Aesthetics adds two FDA-approved Belotero HA fillers for midface volume and lip fullness, promising natural movement and long-lasting results.
Are beef tallow balms beneficial for the skin or are they just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
FDA review of BOTOX Cosmetic for masseter prominence signals on-label jawline contouring, trial-backed results, clearer dosing guidance, and safer patient counseling.
Are "clean" skin care routines legitimate, or are they just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
Clinicians can bridge the gap between online trends and evidence-based outcomes by leveraging patient curiosity, emphasizing ingredient transparency, and delivering personalized in-office care.
Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
Advertisement
Advertisement
Trending on Dermatology Times
1
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
2
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
3
FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis
4
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
5